When was Tarsus founded?

Tarsus was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is Tarsus located?

Tarsus is headquartered in Irvine, United States. It is registered at 15440 Laguna Canyon Road, Suite 160 Irvine, CA 92618.

How many employees does Tarsus have?

As of Jul 31, 2026, the latest employee count at Tarsus is 441.

Is Tarsus a funded company?

Tarsus is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Jan 08, 2020.

How much is Tarsus worth?

The last known valuation of Tarsus was $***** as of Oct 09, 2020.

When was the latest funding round of Tarsus?

Tarsus' latest funding was a $***** Series B round on Jan 08, 2020, with participation from 6 investors.

What is the annual revenue of Tarsus?

Annual revenue of Tarsus is between $100M and $500M as on Dec 31, 2025

Where does Tarsus rank among its competitors?

Tarsus ranks 1st amongst 4 active competitors, none of which are funded.

Who are the top competitors of Tarsus?

Tarsus' top competitors include Aperta Biosciences, Levation Pharma and Novax Pharma. Among them, Tarsus secured the most recent funding round in January, 2020.

Tarsus - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Tarsus is developing a drug to treat blepharitis. The lead compound is a topical ophthalmic drug called TP-03 developed for the treatment of Demodex blepharitis will undergo Phase 2b/3 trials. The company's product pipeline also includes the development of drugs for other eye problems.

Website: tarsusrx.com
Email ID: *****@tarsusrx.com
Phone Number: +1 **********
Registered Address: 15440 Laguna Canyon Road, Suite 160 Irvine, CA 92618

Key Metrics

Founded Year

2017

Location

Irvine, United States

Stage

Acquired

Total Funding

$60M in 1 round

Latest Funding Round

Series B, Jan 08, 2020, $*****

Last Known Valuation

$***** as on Oct 09, 2020

Investors

Vivo Capital & 6 more

Ranked

1^st among 4 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

441 as on Jul 31, 2026

Investment & Acquisitions

Alkeus Pharmaceuticals

Similar Companies

Aperta Biosciences & 2 more

Exit Details

Acquired by Portage Biotech (Jul 07, 2022)

View Tarsus' full profile

Tarsus is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TARSUS PHARMACEUTICALS, INC. CIN: 6134500 , United States, Active	Nov 16, 2016	$100M - $500M (As on Dec 31, 2025)	46 (As on Dec 31, 2021)	-
Tarsus Pharmaceuticals, Inc. CIN: 6599548 , United States, Active	Sep 26, 2022	-	-	-
TARSUS PHARMACEUTICALS, INC. CIN: 199251290 , United States, Active	Jul 14, 2022	-	-	-

Tarsus got acquired by Portage Biotech on Jul 07, 2022.

Click here to take a look at Tarsus's acquisition in detail

Tarsus has raised a total funding of $60M over 1 round. Its latest funding round was a Series B round on Jan 08, 2020 for $*****. 6 investors participated in its latest round. Tarsus has 7 institutional investors.

Here is the list of recent funding rounds of Tarsus:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2020	4740018	Series B	8661833	2850770	9404496	2534286

Access funding benchmarks and valuations. Sign up today!

View details of Tarsus's funding rounds and investors

Tarsus' employee count trend

Tarsus has 441 employees as of Jul 26. Here is Tarsus's employee count trend over the years:

Uncover Tarsus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tarsus include Aperta Biosciences, Levation Pharma and Novax Pharma. Here is the list of Top 10 competitors of Tarsus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tarsus 2017, Irvine (United States), Acquired	Provider of propriety drugs for treating blepharitis disease	$60M	RTW Investments, Vivo Capital & 5 others	66/100
2nd	Aperta Biosciences 2017, Austin (United States), Unfunded	Developer of therapeutics solutions to treat blepharitis and ocular surface disease	-	-	27/100
3rd	Levation Pharma Tel Aviv (Israel), Unfunded	Developer of therapeutics for ophthalmic diseases	-	-	16/100
4th	Novax Pharma 2008, Monaco (Monaco), Unfunded	Manufacturer of ophthalmic medical devices including lubricating eye care solutions	-	-	-